Oliver Keown is a partner of Intuitive Ventures. He joined Intuitive Ventures in 2019 and leads the fund’s investment efforts with a focus on identifying future leaders of minimally invasive care, including early stage startups across digital, medical device, therapeutic and diagnostic domains.

In 2021, Oliver was recognized as a Top 50 Emerging Leader in corporate venture capital and in 2022, selected as #39 on the Global Corporate Venturing Power List of the 100 most influential investors in the industry. Before coming to Intuitive Ventures, Oliver was a healthcare investor with GE Ventures, driving international startup deal flow and supporting portfolio companies operationally and at the board level. Prior to that, he advised an array of UK, US and global healthcare innovation projects across technology, government, commercial, and academic fields. He began his career as a doctor and policy advisor in the UK National Health Service. He remains dedicated to bringing new technologies, diverse partnerships and investment to address healthcare‘s biggest unmet needs.

He is a widely published author in the fields of healthcare and surgical innovation, and is an advisory board member of the Newsom administration‘s California Initiative to Advance Precision Medicine. Oliver serves as an investor and Board Observer of Intuitive Ventures portfolio companies, Medcrypt, Flywheel.io, Endogenex, SurgeTx, Optellum and KelaHealth.

Oliver holds an MD and BSc in pharmacology from the University of Edinburgh, Scotland.